Marksans Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Marksans Pharma Ltd. on BSE

Search Inside the pdf :

Marksans Pharma Ltd.

03 Nov 2025, 12:13PM

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"

BSE India

Notification for all shareholders regarding the last stage of 100 days campaign.

pdf

Marksans Pharma Ltd.

31 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

The Company has scheduled a conference call for analysts and investors on Friday, November 14, 2025 at 05:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

pdf

Marksans Pharma Ltd.

27 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - ESG Score By CFC Finlease Private Limited (Voluntary)

BSE India

CFC Finlease Private Limited , a SEBI lincensed ESG Rating Provider has voluntarily reviewed ESG rating on the Company, based on data available in public domain for fiscal 2025 and assigned an ESG Score of "73".

pdf

Marksans Pharma Ltd.

23 Oct 2025

190.38

4.56%

Board Meeting

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Declaration Of Quarterly Results For The …

BSE India

Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve quarterly results for the Quarter and Nine Months ended September 30, 2025

pdf

Marksans Pharma Ltd.

15 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for it products from UK MHRA.

pdf

Marksans Pharma Ltd.

13 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate received from RTA under 74(5) for the quarter and half year ended September 30, 2025.

pdf

Marksans Pharma Ltd.

08 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

CARE Ratings Limited have upgraded and reaffirmed outlook for the Long term and Short term Bank Facilities

pdf

Marksans Pharma Ltd.

06 Oct 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"

BSE India

100 days campaign notification for all shareholders

pdf

Marksans Pharma Ltd.

25 Sep 2025

190.38

4.56%

SAST

Marksans Pharma Ltd - 524404 - Closure of Trading Window

BSE India

Intimation for closure of trading window for the quarter and half year ended September 2025.

pdf

Marksans Pharma Ltd.

24 Sep 2025

190.38

4.56%

Company Update

Marksans Pharma Ltd - 524404 - Grant Of ESOP Under 'Marksans Employees Stock Option Scheme 2024' …

BSE India

The Nomination and Remuneration Committee (designated Compensation Committee) considered and approved the grant of 4,00,000 option to eligible employees.

pdf

Is Marksans Pharma Ltd. worth buying?

1428 Votes:

Buy 80.53%

Sell 10.15%

Hold 9.31%

46.93% Fall from 52W High

High volume today

Marksans Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Marksans Pharma Ltd. on BSE